Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma

Ivana Micallef, John Apostolidis, Ama Z S Rohatiner, Claire Wiggins, Charles R. Crawley, James M Foran, Marcus Leonhardt, Mike Bradburn, Emily Okukenu, Ashiq Salam, Janet Matthews, Jamie D. Cavenagh, Rajnish K. Gupta, T. Andrew Lister

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

Introduction: High-dose therapy with haematopoietic progenitor cell support has increasingly been utilised for patients with haematological malignancies. Peripheral blood is the stem cell source of choice, however, various mobilisation strategies are used by different centres. Patients and methods: Over a 2-year period, 52 patients with non-Hodgkin's lymphoma (median age 47 years, range 16-64 years) underwent peripheral blood progenitor cell mobilisation using G-CSF alone (16 μg/kg/day). The harvest was considered successful if ≥ 1 × 106 CD34+ cells/kg were collected by leukapheresis. The histological subtypes of non-Hodgkin's lymphoma comprised: follicular (24 patients), diffuse large B-cell (14 patients), lymphoplasmacytoid (four patients), mantle cell (three patients), lymphoblastic lymphoma (one patient) and small lymphocytic lymphoma/chronic lymphocytic leukaemia (six patients). The median interval from diagnosis of non-Hodgkin's lymphoma to mobilisation was 27 months (range 2 months to 17 years). The median number of prior treatment episodes was 2 (range 1-5); 26 patients had received fludarabine alone or in combination. At the time of peripheral blood progenitor cell mobilisation, 20 patients were in 1st remission and 32 were in ≥ 2nd remission; 30 patients were in partial remission and 22 were in complete remission; the bone marrow was involved in nine patients. Results: Peripheral blood progenitor cell mobilisation/harvest was unsuccessful in 19 out of 52 (37%) patients (mobilisation: 18, harvest: 1). The factors associated with unsuccessful mobilisation or harvest were: prior fludarabine therapy (P=0.002), bone marrow involvement at diagnosis (P=0.002), bone marrow involvement anytime prior to mobilisation (P=0.02), histological diagnosis of follicular, mantle cell, or lymphoplasmacytoid lymphoma, or small lymphocytic lymphoma/chronic lymphocytic leukaemia (P=0.03) and female gender (P=0.04). Conclusion: Although peripheral blood progenitor cells can be successfully mobilised and harvested from the majority of patients with non-Hodgkin's lymphoma after treatment with G-CSF alone, the latter is unsuccessful in approximately one-third of patients. These factors should be taken into account when patients are being considered for high-dose treatment.

Original languageEnglish (US)
Pages (from-to)367-373
Number of pages7
JournalHematology Journal
Volume1
Issue number6
StatePublished - 2000
Externally publishedYes

Fingerprint

Granulocyte Colony-Stimulating Factor
Non-Hodgkin's Lymphoma
Blood Cells
Stem Cells
B-Cell Chronic Lymphocytic Leukemia
Bone Marrow
Leukapheresis
Therapeutics
Mantle-Cell Lymphoma
Waldenstrom Macroglobulinemia
Hematologic Neoplasms
Hematopoietic Stem Cells
Precursor Cell Lymphoblastic Leukemia-Lymphoma

Keywords

  • G-CSF
  • Lymphoma
  • Peripheral blood progenitor cell mobilisation

ASJC Scopus subject areas

  • Hematology

Cite this

Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma. / Micallef, Ivana; Apostolidis, John; Rohatiner, Ama Z S; Wiggins, Claire; Crawley, Charles R.; Foran, James M; Leonhardt, Marcus; Bradburn, Mike; Okukenu, Emily; Salam, Ashiq; Matthews, Janet; Cavenagh, Jamie D.; Gupta, Rajnish K.; Lister, T. Andrew.

In: Hematology Journal, Vol. 1, No. 6, 2000, p. 367-373.

Research output: Contribution to journalArticle

Micallef, I, Apostolidis, J, Rohatiner, AZS, Wiggins, C, Crawley, CR, Foran, JM, Leonhardt, M, Bradburn, M, Okukenu, E, Salam, A, Matthews, J, Cavenagh, JD, Gupta, RK & Lister, TA 2000, 'Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma', Hematology Journal, vol. 1, no. 6, pp. 367-373.
Micallef, Ivana ; Apostolidis, John ; Rohatiner, Ama Z S ; Wiggins, Claire ; Crawley, Charles R. ; Foran, James M ; Leonhardt, Marcus ; Bradburn, Mike ; Okukenu, Emily ; Salam, Ashiq ; Matthews, Janet ; Cavenagh, Jamie D. ; Gupta, Rajnish K. ; Lister, T. Andrew. / Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma. In: Hematology Journal. 2000 ; Vol. 1, No. 6. pp. 367-373.
@article{aaf41d409ed44bf295c97c989d21da97,
title = "Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma",
abstract = "Introduction: High-dose therapy with haematopoietic progenitor cell support has increasingly been utilised for patients with haematological malignancies. Peripheral blood is the stem cell source of choice, however, various mobilisation strategies are used by different centres. Patients and methods: Over a 2-year period, 52 patients with non-Hodgkin's lymphoma (median age 47 years, range 16-64 years) underwent peripheral blood progenitor cell mobilisation using G-CSF alone (16 μg/kg/day). The harvest was considered successful if ≥ 1 × 106 CD34+ cells/kg were collected by leukapheresis. The histological subtypes of non-Hodgkin's lymphoma comprised: follicular (24 patients), diffuse large B-cell (14 patients), lymphoplasmacytoid (four patients), mantle cell (three patients), lymphoblastic lymphoma (one patient) and small lymphocytic lymphoma/chronic lymphocytic leukaemia (six patients). The median interval from diagnosis of non-Hodgkin's lymphoma to mobilisation was 27 months (range 2 months to 17 years). The median number of prior treatment episodes was 2 (range 1-5); 26 patients had received fludarabine alone or in combination. At the time of peripheral blood progenitor cell mobilisation, 20 patients were in 1st remission and 32 were in ≥ 2nd remission; 30 patients were in partial remission and 22 were in complete remission; the bone marrow was involved in nine patients. Results: Peripheral blood progenitor cell mobilisation/harvest was unsuccessful in 19 out of 52 (37{\%}) patients (mobilisation: 18, harvest: 1). The factors associated with unsuccessful mobilisation or harvest were: prior fludarabine therapy (P=0.002), bone marrow involvement at diagnosis (P=0.002), bone marrow involvement anytime prior to mobilisation (P=0.02), histological diagnosis of follicular, mantle cell, or lymphoplasmacytoid lymphoma, or small lymphocytic lymphoma/chronic lymphocytic leukaemia (P=0.03) and female gender (P=0.04). Conclusion: Although peripheral blood progenitor cells can be successfully mobilised and harvested from the majority of patients with non-Hodgkin's lymphoma after treatment with G-CSF alone, the latter is unsuccessful in approximately one-third of patients. These factors should be taken into account when patients are being considered for high-dose treatment.",
keywords = "G-CSF, Lymphoma, Peripheral blood progenitor cell mobilisation",
author = "Ivana Micallef and John Apostolidis and Rohatiner, {Ama Z S} and Claire Wiggins and Crawley, {Charles R.} and Foran, {James M} and Marcus Leonhardt and Mike Bradburn and Emily Okukenu and Ashiq Salam and Janet Matthews and Cavenagh, {Jamie D.} and Gupta, {Rajnish K.} and Lister, {T. Andrew}",
year = "2000",
language = "English (US)",
volume = "1",
pages = "367--373",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "6",

}

TY - JOUR

T1 - Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma

AU - Micallef, Ivana

AU - Apostolidis, John

AU - Rohatiner, Ama Z S

AU - Wiggins, Claire

AU - Crawley, Charles R.

AU - Foran, James M

AU - Leonhardt, Marcus

AU - Bradburn, Mike

AU - Okukenu, Emily

AU - Salam, Ashiq

AU - Matthews, Janet

AU - Cavenagh, Jamie D.

AU - Gupta, Rajnish K.

AU - Lister, T. Andrew

PY - 2000

Y1 - 2000

N2 - Introduction: High-dose therapy with haematopoietic progenitor cell support has increasingly been utilised for patients with haematological malignancies. Peripheral blood is the stem cell source of choice, however, various mobilisation strategies are used by different centres. Patients and methods: Over a 2-year period, 52 patients with non-Hodgkin's lymphoma (median age 47 years, range 16-64 years) underwent peripheral blood progenitor cell mobilisation using G-CSF alone (16 μg/kg/day). The harvest was considered successful if ≥ 1 × 106 CD34+ cells/kg were collected by leukapheresis. The histological subtypes of non-Hodgkin's lymphoma comprised: follicular (24 patients), diffuse large B-cell (14 patients), lymphoplasmacytoid (four patients), mantle cell (three patients), lymphoblastic lymphoma (one patient) and small lymphocytic lymphoma/chronic lymphocytic leukaemia (six patients). The median interval from diagnosis of non-Hodgkin's lymphoma to mobilisation was 27 months (range 2 months to 17 years). The median number of prior treatment episodes was 2 (range 1-5); 26 patients had received fludarabine alone or in combination. At the time of peripheral blood progenitor cell mobilisation, 20 patients were in 1st remission and 32 were in ≥ 2nd remission; 30 patients were in partial remission and 22 were in complete remission; the bone marrow was involved in nine patients. Results: Peripheral blood progenitor cell mobilisation/harvest was unsuccessful in 19 out of 52 (37%) patients (mobilisation: 18, harvest: 1). The factors associated with unsuccessful mobilisation or harvest were: prior fludarabine therapy (P=0.002), bone marrow involvement at diagnosis (P=0.002), bone marrow involvement anytime prior to mobilisation (P=0.02), histological diagnosis of follicular, mantle cell, or lymphoplasmacytoid lymphoma, or small lymphocytic lymphoma/chronic lymphocytic leukaemia (P=0.03) and female gender (P=0.04). Conclusion: Although peripheral blood progenitor cells can be successfully mobilised and harvested from the majority of patients with non-Hodgkin's lymphoma after treatment with G-CSF alone, the latter is unsuccessful in approximately one-third of patients. These factors should be taken into account when patients are being considered for high-dose treatment.

AB - Introduction: High-dose therapy with haematopoietic progenitor cell support has increasingly been utilised for patients with haematological malignancies. Peripheral blood is the stem cell source of choice, however, various mobilisation strategies are used by different centres. Patients and methods: Over a 2-year period, 52 patients with non-Hodgkin's lymphoma (median age 47 years, range 16-64 years) underwent peripheral blood progenitor cell mobilisation using G-CSF alone (16 μg/kg/day). The harvest was considered successful if ≥ 1 × 106 CD34+ cells/kg were collected by leukapheresis. The histological subtypes of non-Hodgkin's lymphoma comprised: follicular (24 patients), diffuse large B-cell (14 patients), lymphoplasmacytoid (four patients), mantle cell (three patients), lymphoblastic lymphoma (one patient) and small lymphocytic lymphoma/chronic lymphocytic leukaemia (six patients). The median interval from diagnosis of non-Hodgkin's lymphoma to mobilisation was 27 months (range 2 months to 17 years). The median number of prior treatment episodes was 2 (range 1-5); 26 patients had received fludarabine alone or in combination. At the time of peripheral blood progenitor cell mobilisation, 20 patients were in 1st remission and 32 were in ≥ 2nd remission; 30 patients were in partial remission and 22 were in complete remission; the bone marrow was involved in nine patients. Results: Peripheral blood progenitor cell mobilisation/harvest was unsuccessful in 19 out of 52 (37%) patients (mobilisation: 18, harvest: 1). The factors associated with unsuccessful mobilisation or harvest were: prior fludarabine therapy (P=0.002), bone marrow involvement at diagnosis (P=0.002), bone marrow involvement anytime prior to mobilisation (P=0.02), histological diagnosis of follicular, mantle cell, or lymphoplasmacytoid lymphoma, or small lymphocytic lymphoma/chronic lymphocytic leukaemia (P=0.03) and female gender (P=0.04). Conclusion: Although peripheral blood progenitor cells can be successfully mobilised and harvested from the majority of patients with non-Hodgkin's lymphoma after treatment with G-CSF alone, the latter is unsuccessful in approximately one-third of patients. These factors should be taken into account when patients are being considered for high-dose treatment.

KW - G-CSF

KW - Lymphoma

KW - Peripheral blood progenitor cell mobilisation

UR - http://www.scopus.com/inward/record.url?scp=0034585610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034585610&partnerID=8YFLogxK

M3 - Article

VL - 1

SP - 367

EP - 373

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 6

ER -